Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
17. lappuse
... tion with the directions for use , clear warning statements against : ( a ) Prolonged use . ( b ) Application to large areas of the body . ( c ) Continued use if redness , irrita- tion , swelling , or pain persists or in- creases ...
... tion with the directions for use , clear warning statements against : ( a ) Prolonged use . ( b ) Application to large areas of the body . ( c ) Continued use if redness , irrita- tion , swelling , or pain persists or in- creases ...
18. lappuse
... tion with the directions for use , a clear warning statement , such as : " Caution : If redness , irritation , swelling , or pain persists or increases , discontinue use and consult physician . " ( 23 ) Dyclonine hydrochloride ( 4 - but ...
... tion with the directions for use , a clear warning statement , such as : " Caution : If redness , irritation , swelling , or pain persists or increases , discontinue use and consult physician . " ( 23 ) Dyclonine hydrochloride ( 4 - but ...
23. lappuse
... tion regulations in part 20 of this chap- ter . ( f ) Recordkeeping . ( 1 ) Each manufac- turer , packer , and ... tion submitted by a manufacturer , packer , or distributor under this sec- tion ( and any release by FDA of that report or ...
... tion regulations in part 20 of this chap- ter . ( f ) Recordkeeping . ( 1 ) Each manufac- turer , packer , and ... tion submitted by a manufacturer , packer , or distributor under this sec- tion ( and any release by FDA of that report or ...
30. lappuse
... tion of the arrhythmia is urgent , approxi- mately 0.5 milliequivalents / kilogram of po- tassium per hour may be given , with careful electrocardiographic monitoring , as a solu- tion of 20 milliequivalents or less per 500 mil ...
... tion of the arrhythmia is urgent , approxi- mately 0.5 milliequivalents / kilogram of po- tassium per hour may be given , with careful electrocardiographic monitoring , as a solu- tion of 20 milliequivalents or less per 500 mil ...
35. lappuse
... tion . Do ...... do Red blood cell label- ing and survival Do Labeled human serum albumin . Do ...... do studies . Gastrointestinal pro- tein loss studies . Placenta localiza- tion . Do Labeled red blood Do. Cobalt 58 or Cobalt 60 ...
... tion . Do ...... do Red blood cell label- ing and survival Do Labeled human serum albumin . Do ...... do studies . Gastrointestinal pro- tein loss studies . Placenta localiza- tion . Do Labeled red blood Do. Cobalt 58 or Cobalt 60 ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning